Tobin Schilke Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Tobin Schilke.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Tobin Schilke. Tobin Schilke is Chief Financial Officer in Achaogen Inc ($AKAO) and CFO in Revance Therapeutics, Inc. ($RVNC).
Latest Insider Trading Transactions of Tobin Schilke
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 28.97 | 1,973 | 57,158 | 68,762 | 70.7 K to 68.8 K (-2.79 %) |
| Feb 19 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 28.97 | 684 | 19,815 | 70,735 | 71.4 K to 70.7 K (-0.96 %) |
| Feb 04 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 28.01 | 40,925 | 1,146,309 | 40,925 | |
| Feb 04 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 22,620 | 0 | 71,419 | 48.8 K to 71.4 K (+46.35 %) |
| Jan 04 2021 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 21.36 | 493 | 10,531 | 48,799 | 48.3 K to 48.8 K (+1.02 %) |
| Dec 22 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 26.75 | 1,556 | 41,623 | 48,306 | 49.9 K to 48.3 K (-3.12 %) |
| Oct 02 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 25.14 | 5,446 | 136,912 | 49,862 | 55.3 K to 49.9 K (-9.85 %) |
| Oct 02 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 15,750 | 0 | 55,308 | 39.6 K to 55.3 K (+39.81 %) |
| Jul 02 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 13.80 | 763 | 10,526 | 39,558 | 38.8 K to 39.6 K (+1.97 %) |
| Feb 19 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 25.33 | 576 | 14,590 | 38,795 | 39.4 K to 38.8 K (-1.46 %) |
| Jan 24 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 22.32 | 97,500 | 2,176,200 | 97,500 | |
| Jan 24 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 16,500 | 0 | 39,371 | 22.9 K to 39.4 K (+72.14 %) |
| Jan 03 2020 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 10.82 | 504 | 5,453 | 22,871 | 22.4 K to 22.9 K (+2.25 %) |
| Dec 17 2019 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Payment of Exercise | F | 15.99 | 1,556 | 24,880 | 22,367 | 23.9 K to 22.4 K (-6.50 %) |
| Jul 02 2019 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Buy | J | 11.02 | 923 | 10,176 | 23,923 | 23 K to 23.9 K (+4.01 %) |
| Jan 25 2019 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 17.23 | 30,000 | 516,900 | 30,000 | |
| Jan 25 2019 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 5,000 | 0 | 23,000 | 18 K to 23 K (+27.78 %) |
| Nov 07 2018 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 24.96 | 100,000 | 2,496,000 | 100,000 | |
| Nov 07 2018 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 18,000 | 0 | 18,000 | 0 to 18 K |
| Nov 07 2018 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Option Exercise | A | 24.96 | 100,000 | 2,496,000 | 100,000 | |
| Nov 07 2018 | RVNC | Revance Therapeuti ... | Schilke Tobin | CFO | Grant | A | 0.00 | 18,000 | 0 | 18,000 | 0 to 18 K |
| Jun 28 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Option Exercise | A | 10.64 | 4,000 | 42,560 | 4,000 | |
| Jun 28 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Sell | S | 9.59 | 298 | 2,858 | 47,748 | 48 K to 47.7 K (-0.62 %) |
| Jun 28 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Grant | A | 0.00 | 860 | 0 | 48,046 | 47.2 K to 48 K (+1.82 %) |
| Jun 13 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Sell | S | 11.95 | 2,087 | 24,940 | 47,186 | 49.3 K to 47.2 K (-4.24 %) |
| May 15 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Option Exercise | A | 10.64 | 32,000 | 340,480 | 32,000 | |
| May 15 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Grant | A | 0.00 | 6,880 | 0 | 47,065 | 40.2 K to 47.1 K (+17.12 %) |
| Feb 23 2018 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Sell | S | 10.67 | 1,108 | 11,822 | 40,185 | 41.3 K to 40.2 K (-2.68 %) |
| Jun 14 2017 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Sell | S | 21.53 | 2,066 | 44,481 | 40,119 | 42.2 K to 40.1 K (-4.90 %) |
| Feb 24 2017 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Option Exercise | A | 23.62 | 12,600 | 297,612 | 12,600 | |
| Feb 24 2017 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Option Exercise | A | 23.62 | 50,400 | 1,190,448 | 50,400 | |
| Feb 24 2017 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Grant | A | 0.00 | 13,500 | 0 | 39,545 | 26 K to 39.5 K (+51.83 %) |
| Jan 30 2017 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Sell | S | 16.78 | 955 | 16,025 | 26,045 | 27 K to 26 K (-3.54 %) |
| Jul 06 2016 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Option Exercise | A | 4.09 | 26,000 | 106,340 | 26,000 | |
| Jul 06 2016 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Option Exercise | A | 4.09 | 100,000 | 409,000 | 100,000 | |
| Jul 06 2016 | AKAO | Achaogen Inc | Schilke Tobin | Chief Financial Off ... | Grant | A | 0.00 | 27,000 | 0 | 27,000 | 0 to 27 K |
Page: 1